Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

被引：5
|
作者：
Minchom, Anna Rachel
Girard, Nicolas
Bazhenova, Lyudmila
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Trigo, Jose
Viteri, Santiago
Backenroth, Daniel
Bhattacharya, Archan
Li, Tracy
Mahadevia, Parthiv
Bauml, Joshua
机构：
[1] Royal Marsden Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[2] Inst Curie, Paris, France
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ Calif Irvine, Orange, CA 92668 USA
[5] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI USA
[6] IBIMA, Hosp Univ Virgen Victoria & Reg, Malaga, Spain
[7] Grp QuironSalud, Ctr Med Teknon, Inst Oncol Dr Rosell, Barcelona, Spain
[8] Janssen R&D, Raritan, NJ USA
[9] Janssen R&D, High Wycombe, PA, England
[10] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9052
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
    Helen Mann
    Frank Andersohn
    Carolyn Bodnar
    Tetsuya Mitsudomi
    Tony S. K. Mok
    James Chih-Hsin Yang
    Christopher Hoyle
    Clinical Drug Investigation, 2018, 38 : 319 - 331
  • [32] Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
    Mann, Helen
    Andersohn, Frank
    Bodnar, Carolyn
    Mitsudomi, Tetsuya
    Mok, Tony S. K.
    Yang, James Chih-Hsin
    Hoyle, Christopher
    CLINICAL DRUG INVESTIGATION, 2018, 38 (04) : 319 - 331
  • [33] Real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion
    Viteri, S.
    Bauml, J. M.
    Bazhenova, L.
    Ou, S-H. I.
    Girard, N.
    Schaffer, M.
    Rose, J.
    Curtin, J.
    Karkera, J.
    Mahadevia, P.
    Minchom, A. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S699 - S699
  • [34] Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe
    Girard, N.
    Wolf, J.
    Kim, T. M.
    Leighl, N.
    Knott, C.
    Li, T.
    Cabrieto, J.
    Diels, J.
    Sermon, J.
    Mahadevia, P.
    Schioppa, C. A.
    Sabari, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S56 - S56
  • [35] Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
    Shi, Chao
    Xing, Ruyue
    Li, Mengmeng
    Feng, Junnan
    Sun, Rui
    Wei, Bing
    Guo, Yongjun
    Ma, Jie
    Wang, Huijuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.
    Janne, Pasi A.
    Wang, Mengzhao
    Camidge, D. Ross
    Mitchell, Paul
    Fang, Jian
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Yang, Tsung-Ying
    Zhu, Viola Weijia
    Millward, Michael
    Fan, Yun
    Huang, Wen-Tsung
    Cheng, Ying
    Jiang, Liyan
    Brungs, Daniel
    Zheng, Li
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
    Manegold, Christian
    Adjei, Alex
    Bussolino, Federico
    Cappuzzo, Federico
    Crino, Lucio
    Dziadziuszko, Rafal
    Ettinger, David
    Fennell, Dean
    Kerr, Keith
    Le Chevalier, Thierry
    Leighl, Natasha
    Papotti, Mauro
    Paz-Ares, Luis
    Perol, Maurice
    Peters, Solange
    Pirker, Robert
    Quoix, Elisabeth
    Reck, Martin
    Smit, Egbert
    Vokes, Everett
    van Zandwijk, Nico
    Zhou, Caicun
    ESMO OPEN, 2016, 1 (06)
  • [38] Amivantamab vs real-world (RW) therapies for advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (E20i) in Japan
    Okahisa, M.
    Udagawa, H.
    Matsumoto, S.
    Kato, T.
    Yokouchi, H.
    Furuya, N.
    Kanemaru, R.
    Toyozawa, R.
    Nishiyama, A.
    Ohashi, K.
    Miyamoto, S.
    Nishino, K.
    Oi, H.
    Low, G. K. M.
    Zhuo, J.
    Yu, D. Young
    Yang, Y.
    Lim, C.
    Kleinman, N. J.
    Goto, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1061 - S1061
  • [39] Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI
    Andersohn, F.
    Mann, H.
    Mitsudomi, T.
    Mok, T. S. K.
    Yang, J. Chih-Hsin
    Papadakis, K.
    Hoyle, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Real-world effectiveness and safety of amivantamab for exon 20 EGFR-mutant non-small cell lung cancer (NSCLC) in French early access program: Amexon 20 GFPC
    Pierret, Thomas
    Guisier, Florian
    Daniel, Catherine
    Descourt, Renaud
    Galland, Loick
    Molinier, Olivier
    Decroisette, Chantal
    Cortot, Alexis B.
    Moreau, Diane
    Bigay-Game, Laurence
    Wislez, Marie
    Cloarec, Nicolas
    Curcio, Hubert
    Delberghe, Nicolas
    Cadranel, Jacques
    Duchemann, Boris
    Toffart, Anne-Claire
    Moreau, Lionel
    Greillier, Laurent
    Auliac, Jean-Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345